Mesenchymal stem cell transplantation in the treatment of bronchopulmonary dysplasia: opportunities and challenges.
- Author:
Lei BAO
1
;
Yuan SHI
Author Information
1. Department of Neonatology, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Engineering Research Center of Stem Cell Therapy, Chongqing 400014, China. petshi530@vip.163.com.
- Publication Type:Journal Article
- MeSH:
Bronchopulmonary Dysplasia;
therapy;
Humans;
Infant, Premature;
Mesenchymal Stem Cell Transplantation
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(7):619-623
- CountryChina
- Language:Chinese
-
Abstract:
Bronchopulmonary dysplasia (BPD) is one of the most common chronic lung diseases in neonates especially in preterm infants. It is also the main reason leading to a poor prognosis. The prognosis of the neonates with BPD is unsatisfactory with current treatment strategies. Recent clinical trails have found that mesenchymal stem cell (MSC) transplantation might be effective and promising for treatment of BPD in neonates. This article outlines the characteristics of MSC and the potential mechanisms of MSC transplantation for BPD in vivo, and the safety and feasibility of MSC transplantation in BPD neonates, as well as the challenges in clinical trials on MSC transplantation for treatment of BPD.
